Trask Peter C
Centers for Behavioral and Preventive Medicine, Coro Building, Ste. 500, 1 Hoppin St., Providence, RI 02903, USA.
J Natl Cancer Inst Monogr. 2004(32):80-92. doi: 10.1093/jncimonographs/lgh013.
It is widely known that depression exists in patients with cancer. The prevalence, however, varies widely by study and is often attributable to differences in assessment procedures. Attempts to identify accurate methods of assessing depression in cancer patients have employed different diagnostic approaches, assessment methods (e.g., self-report versus interview), and inclusion criteria. Unfortunately, all of these variables affect conclusions that can be drawn regarding the presence of depression in cancer patients. Other variables that can further affect the assessment of depression in cancer patients include individual differences such as the patient's age, gender, race/ethnicity, hospitalization status, and type and stage of cancer. Finally, the specific assessor and the timing of the assessment also likely affect conclusions about depression in cancer patients. This review was designed to succinctly address all of the above issues and identify several areas for future research, including refining diagnostic criteria for depression in cancer patients; creating cancer-specific depression measures with appropriate cutoffs; focusing on the issues of age, race, ethnicity, subculture, and type and stage of cancer in creating depression assessment tools; and exploring the issues of clinical versus subclinical depression, who and when to assess, and timely and cost-effective ways to assess.
众所周知,癌症患者中存在抑郁症。然而,其患病率因研究而异,且往往归因于评估程序的差异。为确定评估癌症患者抑郁症的准确方法,人们采用了不同的诊断方法、评估方法(如自我报告与访谈)和纳入标准。不幸的是,所有这些变量都会影响关于癌症患者是否存在抑郁症的结论。其他可能进一步影响癌症患者抑郁症评估的变量包括个体差异,如患者的年龄、性别、种族/民族、住院状况以及癌症的类型和分期。最后,具体的评估者和评估时间也可能影响关于癌症患者抑郁症的结论。本综述旨在简要阐述上述所有问题,并确定未来研究的几个领域,包括完善癌症患者抑郁症的诊断标准;制定具有适当临界值的癌症特异性抑郁症测量方法;在创建抑郁症评估工具时关注年龄、种族、民族、亚文化以及癌症的类型和分期等问题;探讨临床抑郁症与亚临床抑郁症、评估对象和时间以及及时且经济有效的评估方法等问题。